Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) – Investment analysts at William Blair boosted their FY2027 EPS estimates for shares of Krystal Biotech in a research note issued to investors on Monday, May 22nd. William Blair analyst T. Lugo now expects that the company will earn $8.76 per share for the year, up from their previous estimate of $8.60. William Blair has a “Outperform” rating on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is ($5.85) per share.
A number of other brokerages have also weighed in on KRYS. Bank of America increased their price objective on Krystal Biotech from $105.00 to $118.00 in a report on Sunday. The Goldman Sachs Group raised shares of Krystal Biotech from a “neutral” rating to a “buy” rating and raised their price target for the company from $79.00 to $124.00 in a research note on Tuesday, February 28th. Chardan Capital upped their price objective on shares of Krystal Biotech from $133.00 to $148.00 in a research note on Monday. Stifel Nicolaus began coverage on shares of Krystal Biotech in a research report on Monday, April 17th. They set a “buy” rating and a $102.00 price target on the stock. Finally, HC Wainwright upped their price target on Krystal Biotech from $119.00 to $139.00 in a research note on Monday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $126.83.
Krystal Biotech Stock Performance
Krystal Biotech (NASDAQ:KRYS – Get Rating) last announced its earnings results on Monday, February 27th. The company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.01.
Insider Transactions at Krystal Biotech
In related news, Director Dino A. Rossi sold 40,000 shares of the company’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $83.25, for a total value of $3,330,000.00. Following the completion of the transaction, the director now directly owns 83,691 shares in the company, valued at $6,967,275.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Monday, April 17th. The stock was sold at an average price of $87.65, for a total value of $2,191,250.00. Following the completion of the transaction, the insider now owns 1,649,206 shares in the company, valued at approximately $144,552,905.90. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Dino A. Rossi sold 40,000 shares of the business’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $83.25, for a total transaction of $3,330,000.00. Following the sale, the director now directly owns 83,691 shares of the company’s stock, valued at approximately $6,967,275.75. The disclosure for this sale can be found here. Insiders sold a total of 90,000 shares of company stock valued at $7,786,432 in the last ninety days. Corporate insiders own 17.00% of the company’s stock.
Institutional Trading of Krystal Biotech
A number of institutional investors have recently made changes to their positions in KRYS. Almanack Investment Partners LLC. bought a new position in shares of Krystal Biotech in the third quarter valued at $52,000. Allspring Global Investments Holdings LLC lifted its holdings in Krystal Biotech by 260.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 981 shares of the company’s stock worth $68,000 after purchasing an additional 709 shares during the last quarter. Great West Life Assurance Co. Can lifted its holdings in shares of Krystal Biotech by 51.9% during the first quarter. Great West Life Assurance Co. Can now owns 1,013 shares of the company’s stock worth $72,000 after buying an additional 346 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Krystal Biotech by 148.3% in the first quarter. Tower Research Capital LLC TRC now owns 956 shares of the company’s stock valued at $77,000 after purchasing an additional 571 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Krystal Biotech in the 1st quarter valued at $104,000. 80.80% of the stock is owned by institutional investors and hedge funds.
About Krystal Biotech
Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization.
Read More
- Get a free copy of the StockNews.com research report on Krystal Biotech (KRYS)
- Why Investors Aren’t Kicking Up Their Heels Over Boot Barn Stock?
- monday.com Surges on Price and Volume after Blowout Results
- Can Ryanair Stock Fly Above Resistance Levels, What Earnings Show
- All Aboard! The Sell-Side Has Railroads In ReversalÂ
- Is There Value Left in Lyft Stock?
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
